Skip to main content
SpringerLink
Log in

Adverse Metabolic Effects Associated with Atypical Antipsychotics

Literature Review and Clinical Implications

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Adverse metabolic effects, such as diabetes mellitus, lipid abnormalities and weight gain, have increasingly been recognised with the use of the newer, so-called atypical antipsychotic drugs. This article reviews the current literature in the field and attempts to answer the question of whether the atypical antipsychotics differ in their effects on glucose-insulin homeostasis and lipid metabolism. It also addresses how then to manage the use of the atypical antipsychotics that do interfere with these metabolic systems. Differences in effects of atypical antipsychotics on leptin levels are also summarised and put into context; bodyweight gain associated with atypical antipsychotics is reviewed elsewhere.

In summary, there are no large controlled trials published quantifying the prevalence of adverse effects on glucose-insulin homeostasis and lipid metabolism in patients receiving atypical antipsychotics. Nevertheless, the published articles and case reports reviewed in this article give a fairly good view of those adverse effects occurring with clozapine, olanzapine and risperidone, whereas little data are available regarding quetiapine, ziprasidone and zotepine, and no data exist for amisulpride and aripiprazole. Estimated rankings of the atypical agents, based on the available literature, show that the relative risk of glucose intolerance/diabetes mellitus, hyperlipidaemia and hyperleptinaemia is highest for clozapine and olanzapine, moderately high for quetiapine, rather low for risperidone and lowest for ziprasidone. Since adverse metabolic effects of atypical antipsychotics may have a negative influence on both the antipsychotic treatment outcome as well as the physical health of the patient, these effects have to be recognised and adequately managed. In this review, recommendations for prevention and treatment of the adverse metabolic effects are outlined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Hiles BW. Hyperglycemia and glucosuria following chlorpromazine therapy [letter]. JAMA 1956; 162: 1651

    Article  Google Scholar 

  2. Cooperberg AA, Eidlow S. Haemolytic anaemia, jaundice and diabetes mellitus following chlorpromazine therapy. CMAJ 1956; 75: 746–9

    CAS  Google Scholar 

  3. Amdisen A. Diabetes mellitus as a side effect of treatment with tricyclic neuroleptics. Acta Psychiatr Scand 1964; 40 (180 Suppl.): 411–4

    Article  PubMed  Google Scholar 

  4. Korenyi C, Lowenstein B. Chlorpromazine induced diabetes. Dis Nerv Syst 1968; 29: 827–8

    PubMed  CAS  Google Scholar 

  5. Schwarz L, Munoz R. Blood sugar levels in patients treated with chlorpromazine. Am J Psychiatry 1968; 125: 253–5

    PubMed  CAS  Google Scholar 

  6. Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 1968; 124: 978–82

    PubMed  CAS  Google Scholar 

  7. Mefferd RB, Labrosse EH, Gawienowski AM, et al. Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics. J Nerv Ment Dis 1958; 127: 167–79

    Article  PubMed  CAS  Google Scholar 

  8. Clark ML, Ray TS, Paredes A, et al. Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol-behavior relationships. Psychosom Med 1967; 29: 634–42

    PubMed  CAS  Google Scholar 

  9. Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clin Pharm Ther 1970; 11: 883–9

    CAS  Google Scholar 

  10. Taylor DM, McAskill R. Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatr Scand 2000; 101: 416–32

    Article  PubMed  CAS  Google Scholar 

  11. Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 2001; 15: 537–51

    Article  PubMed  CAS  Google Scholar 

  12. Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry 2001; 62 (23 Suppl.): 5–12

    Article  PubMed  CAS  Google Scholar 

  13. Wetterling T. Bodyweight gain with atypical antipsychotics: a comparative review. Drug Saf 2001; 24: 59–73

    Article  PubMed  CAS  Google Scholar 

  14. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003; 28: 83–96

    Article  PubMed  CAS  Google Scholar 

  15. Keck P, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 1998; 140: 173–84

    Article  PubMed  CAS  Google Scholar 

  16. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/ day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999; 20: 491–505

    Article  PubMed  CAS  Google Scholar 

  17. Kingsbury SJ, Fayek M, Trufasiu D, et al. The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry 2001; 62: 347–9

    Article  PubMed  CAS  Google Scholar 

  18. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62: 92–100

    Article  PubMed  CAS  Google Scholar 

  19. Zimmet PZ. Kelly West Lecture 1991. Challenges in diabetes epidemiology: from West to the rest. Diabetes Care 1992; 15: 232–52

    PubMed  CAS  Google Scholar 

  20. Olefsky JM. Insulin resistance. In: Porte D, Sherwin RS, editors. Diabetes mellitus. 5th ed. Stamford (CT): Appleton & Lange, 1997: 513–52

    Google Scholar 

  21. Comi RJ. Drug-induced diabetes mellitus. In: LeRoith D, Taylor SI, Olefsky JM, editors. Diabetes mellitus: a fundamental and clinical text. Philadelphia (PA): Lippincott Williams & Wilkins, 2000: 582–8

    Google Scholar 

  22. Yazici KM, Erbas T, Yazici AH. The effect of clozapine on glucose metabolism. Exp Clin Endocrinol Diabetes 1998; 106: 475–7

    Article  PubMed  CAS  Google Scholar 

  23. Hägg S, Joelsson L, Mjörndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998; 59: 294–9

    Article  PubMed  Google Scholar 

  24. Melkersson KI, Hulting AL, Brismar KE. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 1999; 60: 783–91

    Article  PubMed  CAS  Google Scholar 

  25. Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology 2003; 170: 157–66

    Article  PubMed  CAS  Google Scholar 

  26. Chae B-J, Kang B-J. The effect of clozapine on blood glucose metabolism. Hum Psychopharmacol Clin Exp 2001; 16: 265–71

    Article  CAS  Google Scholar 

  27. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157: 975–81

    Article  PubMed  CAS  Google Scholar 

  28. Leonard P, Halley A, Browne S. Prevalence of obesity, lipid and glucose abnormalities in outpatients prescribed clozapine. Ir Med J 2002; 95: 119–20

    PubMed  CAS  Google Scholar 

  29. Sernyak MJ, Gulanski B, Leslie DL, et al. Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia. J Clin Psychiatry 2003; 64: 605–8

    Article  PubMed  CAS  Google Scholar 

  30. Lund BC, Perry PJ, Brooks JM, et al. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 2001; 58: 1172–6

    Article  PubMed  CAS  Google Scholar 

  31. Wang PS, Glynn RJ, Ganz DA, et al. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol 2002; 22: 236–43

    Article  PubMed  CAS  Google Scholar 

  32. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000; 61: 742–9

    Article  PubMed  CAS  Google Scholar 

  33. Lindenmayer J-P, Smith RC, Singh A, et al. Hyperglycemia in patients with schizophrenia who are treated with olanzapine [letter]. J Clin Psychopharmacol 2001; 21: 351–3

    Article  PubMed  CAS  Google Scholar 

  34. Biswas PN, Wilton LV, Pearce GL, et al. The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J Psychopharmacol 2001; 15: 265–71

    Article  CAS  Google Scholar 

  35. Reinstein MJ, Sirotovskaya LA, Jones LE, et al. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control: preliminary findings. Clin Drug Invest 1999; 18: 99–104

    Article  CAS  Google Scholar 

  36. Melamed Y, Mazeh D, Elizur A. Risperidone treatment for a patient suffering from schizophrenia and IDDM [letter]. Can J Psychiatry 1998; 43: 956

    PubMed  CAS  Google Scholar 

  37. Madhusoodanan S, Brenner R, Araujo L, et al. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995; 56: 514–8

    PubMed  CAS  Google Scholar 

  38. Diagnostic and statistical manual of mental disorders, DSM-IV. 4th ed. Washington, DC: American Psychiatric Association, 1994

  39. Melkersson KI, Hulting AL. Insulin and leptin levels in patients with schizophrenia or related psychoses: a comparison between different antipsychotic agents. Psychopharmacology 2001; 154: 205–12

    Article  PubMed  CAS  Google Scholar 

  40. Diagnostic and statistical manual of mental disorders, DSM-III-R. 3rd rev. ed. Washington, DC: American Psychiatric Association, 1987

  41. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59: 337–45

    Article  PubMed  CAS  Google Scholar 

  42. International classification of diseases. 9th rev. Geneva: World Health Organization, 1977

  43. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159: 561–6

    Article  PubMed  Google Scholar 

  44. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcome after 1 year. J Clin Psychiatry 2002; 63: 425–33

    Article  PubMed  CAS  Google Scholar 

  45. Koro CE, Fedder DO, L’Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002; 325: 243–8

    Article  PubMed  CAS  Google Scholar 

  46. Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002; 63: 920–30

    Article  PubMed  CAS  Google Scholar 

  47. Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002; 63: 856–65

    Article  PubMed  CAS  Google Scholar 

  48. Hedenmalm K, Hägg S, Ståhl M, et al. Glucose intolerance with atypical antipsychotics. Drug Saf 2002; 25: 1107–16

    Article  PubMed  CAS  Google Scholar 

  49. Sowell MO, Mukhopadhyay N, Cavazzoni P, et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 2002; 87: 2918–23

    Article  PubMed  CAS  Google Scholar 

  50. Caro JJ, Ward A, Levinton C, et al. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2002; 63: 1135–9

    Article  PubMed  CAS  Google Scholar 

  51. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160: 290–6

    Article  PubMed  Google Scholar 

  52. Croarkin PE, Jacobs KM, Bain BK. Diabetic ketoacidosis associated with risperidone treatment [letter]? Psychosomatics 2000; 41: 369–70

    Article  PubMed  CAS  Google Scholar 

  53. Procyshyn RM, Pande S, Tse G. New-onset diabetes mellitus associated with quetiapine [letter]. Can J Psychiatry 2000; 45: 668–9

    PubMed  CAS  Google Scholar 

  54. Haupt DW, Newcomer JW. Risperidone-associated diabetic ketoacidosis [letter]. J Psychosomatics 2001; 42: 279–80

    Article  CAS  Google Scholar 

  55. Mallya A, Chawla P, Boyer SK, et al. Resolution of hyperglycemia on risperidone discontinuation: a case report [letter]. J Clin Psychiatry 2002; 63: 453–4

    Article  PubMed  Google Scholar 

  56. George K, Alberti MM. Diabetic acidosis, hyperosmolar coma, and lactic acidosis. In: Becker KL, editor. Principles and practice of endocrinology and metabolism. 3rd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2001: 1438–51

    Google Scholar 

  57. Von Hayek D, Hüttl V, Reiss J, et al. Hyperglycaemia and ketoacidosis on olanzapine [in German]. Nervenarzt 1999; 70: 836–7

    Article  Google Scholar 

  58. Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002; 63: 1148–55

    Article  PubMed  CAS  Google Scholar 

  59. Meatherall R, Younes J. Fatality from olanzapine induced hyperglycemia. J Forensic Sci 2002; 47: 893–6

    PubMed  Google Scholar 

  60. Koren W, Kreis Y, Duchowiczny K, et al. Lactic acidosis and fatal myocardial failure due to clozapine. Ann Pharmacother 1997; 31: 168–70

    PubMed  CAS  Google Scholar 

  61. Fertig MK, Brooks VG, Shelton PS, et al. Hyperglycemia associated with olanzapine [letter]. J Clin Psychiatry 1998; 59: 687–9

    Article  PubMed  CAS  Google Scholar 

  62. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44: 778–83

    Article  PubMed  CAS  Google Scholar 

  63. Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999; 40: 438–43

    Article  PubMed  CAS  Google Scholar 

  64. Rigalleau V, Gatta B, Bonnaud S, et al. Diabetes as a result of atypical anti-psychotic drugs: a report of three cases. Diabet Med 2000; 17: 484–6

    Article  PubMed  CAS  Google Scholar 

  65. Ananth J, Gunatilake S, Aquino S, et al. Are African American patients at a higher risk for olanzapine-induced glucose intolerance [letter]? Psychopharmacology 2001; 157: 324–5

    Article  PubMed  CAS  Google Scholar 

  66. Bechara CI, Goldman-Levine JD. Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy. Pharmacotherapy 2001; 21: 1444–7

    Article  PubMed  CAS  Google Scholar 

  67. Bonanno DG, Davydov L, Botts SR. Olanzapine-induced diabetes mellitus. Ann Pharmacother 2001; 35: 563–5

    Article  PubMed  CAS  Google Scholar 

  68. Domon SE, Webber JC. Hyperglycemia and hypertriglyceridemia secondary to olanzapine. J Child Adolesc Psychopharmacol 2001; 11: 285–8

    Article  PubMed  CAS  Google Scholar 

  69. Kropp S, Emrich HM. Olanzapine-related hyperglycemia in a nondiabetic woman [letter]. Can J Psychiatry 2001; 46: 457

    PubMed  CAS  Google Scholar 

  70. Seaburg HL, McLendon BM, Doraiswamy PM. Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature. Pharmacotherapy 2001; 21: 1448–54

    Article  PubMed  CAS  Google Scholar 

  71. Van Meter SA, Seaburg H, McLendon B, et al. Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose [letter]. J Clin Psychiatry 2001; 62: 993–4

    Article  PubMed  Google Scholar 

  72. Melkersson K, Hulting AL. Recovery from new-onset diabetes in a schizophrenic man after withdrawal of olanzapine. Psychosomatics 2002; 43: 67–70

    Article  PubMed  Google Scholar 

  73. Opp D, Hildebrandt C. Olanzapine-associated type 2 diabetes mellitus [letter]. Schizophr Res 2002; 56: 195–6

    Article  PubMed  Google Scholar 

  74. Riccitelli G, Baker N. Weight gain and hyperglycemia associated with olanzapine [letter]. Aust N Z J Psychiatry 2002; 36: 270–1

    PubMed  Google Scholar 

  75. Spivak B, Alamy SS, Jarskog LF, et al. Ziprasidone alternative for olanzapine-induced hyperglycemia [letter]. Am J Psychiatry 2002; 159: 1606

    Article  PubMed  Google Scholar 

  76. Stoner SC, Dubisar BM, Khan R, et al. Severe hypertriglyceridemia associated with olanzapine [letter]. J Clin Psychiatry 2002; 63: 948–9

    Article  PubMed  Google Scholar 

  77. Abdullah N, Voronovitch L, Taylor S, et al. Olanzapine and quick-response hyperglycemia [letter]. Psychosomatics 2003; 44: 175–6

    Article  PubMed  Google Scholar 

  78. Gatta B, Rigalleau V, Gin H. Diabetic ketoacidosis with olanzapine treatment [letter]. Diabetes Care 1999; 22: 1002–3

    Article  PubMed  CAS  Google Scholar 

  79. Lindenmayer JP, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus [letter]. Am J Psychiatry 1999; 156: 1471

    PubMed  CAS  Google Scholar 

  80. Paizis M, Cavaleri S, Schwarz ME, et al. Acute-onset diabetic ketoacidosis during olanzapine treatment in a patient without pretreatment obesity or treatment-associated weight gain. Prim Psychiatry 1999; 6: 37–8

    Google Scholar 

  81. Muench J, Carey M. Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature. J Am Board Fam Pract 2001; 14: 278–82

    PubMed  CAS  Google Scholar 

  82. Ragucci KR, Wells BJ. Olanzapine-induced diabetic ketoacidosis. Ann Pharmacother 2001; 35: 1556–8

    Article  PubMed  CAS  Google Scholar 

  83. Selva KA, Scott SM. Diabetic ketoacidosis associated with olanzapine in an adolescent patient. J Pediatr 2001; 138: 936–8

    Article  PubMed  CAS  Google Scholar 

  84. Johnson RP, Al-Taher MT, Madlock LE, et al. Increasing insulin dose for olanzapine-related diabetes [letter]. Am J Psychiatry 2002; 159: 150–1

    Article  PubMed  Google Scholar 

  85. Straker D, Mendelowitz A, Karlin L. Near fatal ketoacidosis with olanzapine treatment. Psychosomatics 2002; 43: 339–40

    Article  PubMed  Google Scholar 

  86. Wilson DR, D’Souza L, Sarkar N, et al. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 2002; 59: 1–6

    Article  Google Scholar 

  87. Roefaro J, Mukherjee SM. Olanzapine-induced hyperglycemic nonketonic coma. Ann Pharmacother 2001; 35: 300–2

    Article  PubMed  CAS  Google Scholar 

  88. Ober SK, Hudak R, Rusterholtz A. Hyperglycemia and olanzapine [letter]. Am J Psychiatry 1999; 156: 970

    PubMed  CAS  Google Scholar 

  89. Bettinger TL, Mendelson SC, Dorson PG, et al. Olanzapine-induced glucose dysregulation. Ann Pharmacother 2000; 34: 865–7

    Article  PubMed  CAS  Google Scholar 

  90. Malyuk R, Gibson B, Procyshyn RM, et al. Olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome: case report. Int J Geriatr Psychiatry 2002; 17: 326–8

    Article  PubMed  Google Scholar 

  91. Ramankutty G. Olanzapine-induced destabilization of diabetes in the absence of weight gain. Acta Psychiatr Scand 2002; 105: 235–7

    Article  PubMed  CAS  Google Scholar 

  92. Kamran A, Doraiswamy PM, Jane JL, et al. Severe hyperglycemia associated with high doses of clozapine [letter]. Am J Psychiatry 1994; 151: 1395

    PubMed  CAS  Google Scholar 

  93. Popli AP, Konicki PE, Jurjus GJ, et al. Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997; 58: 108–11

    Article  PubMed  CAS  Google Scholar 

  94. Dickson RA, Hogg L. Pregnancy of a patient treated with clozapine. Psychiatr Serv 1998; 49: 1081–3

    PubMed  CAS  Google Scholar 

  95. Thompson J, Chengappa KNR, Good CB, et al. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment. Int Clin Psychopharmacol 1998; 13: 95–8

    Article  PubMed  CAS  Google Scholar 

  96. Isakov I, Klesmer J, Masand PS. Insulin-resistant hyperglycemia induced by clozapine [letter]. Psychosomatics 2000; 41: 373–4

    Article  PubMed  CAS  Google Scholar 

  97. Wehring H, Alexander B, Perry PJ. Diabetes mellitus associated with clozapine therapy. Pharmacotherapy 2000; 20: 844–7

    Article  PubMed  CAS  Google Scholar 

  98. Wu G, Dias P, Wu C, et al. Hyperglycemia, hyperlipidemia, and periodic paralysis: a case report of new side effects of clozapine. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24: 1395–400

    Article  PubMed  CAS  Google Scholar 

  99. Koval MS, Rames LJ, Christie S. Diabetic ketoacidosis associated with clozapine treatment [letter]. Am J Psychiatry 1994; 151: 1520–1

    PubMed  CAS  Google Scholar 

  100. Kostakoglu AE, Yazici KM, Erbas T, et al. Ketoacidosis as a side-effect of clozapine: a case report. Acta Psychiatr Scand 1996; 93: 217–8

    Article  PubMed  CAS  Google Scholar 

  101. Peterson GA, Byrd SL. Diabetic ketoacidosis from clozapine and lithium cotreatment [letter]. Am J Psychiatry 1996; 153: 737–8

    PubMed  CAS  Google Scholar 

  102. Pierides M. Clozapine monotherapy and ketoacidosis [letter]. Br J Psychiatry 1997; 171: 90–1

    Article  PubMed  CAS  Google Scholar 

  103. Ai D, Roper TA, Riley JA. Diabetic ketoacidosis and clozapine. Postgrad Med J 1998; 74: 493–4

    Article  PubMed  CAS  Google Scholar 

  104. Colli A, Cocciolo M, Francobandiera G, et al. Diabetic ketoacidosis associated with clozapine treatment [letter]. Diabetes Care 1999; 22: 176–7

    Article  PubMed  CAS  Google Scholar 

  105. Maule S, Giannella R, Lanzio M, et al. Diabetic ketoacidosis with clozapine treatment [letter]. Diabetes Nutr Metab 1999; 12: 187–8

    PubMed  CAS  Google Scholar 

  106. Mohan D, Gordon H, Hindley N, et al. Schizophrenia and diabetes mellitus [letter]. Br J Psychiatry 1999; 174: 180–1

    Article  PubMed  CAS  Google Scholar 

  107. Smith H, Kenney-Herbert J, Knowles L. Clozapine-induced diabetic ketoacidosis [letter]. Aust N Z J Psychiatry 1999; 33: 120–1

    Article  PubMed  CAS  Google Scholar 

  108. Avram AM, Patel V, Taylor HC, et al. Euglycemic clamp study in clozapine-induced diabetic ketoacidosis. Ann Pharmacother 2001; 35: 1381–7

    Article  PubMed  CAS  Google Scholar 

  109. Nicolai J, Smith SJ, Keunen RWM. Simultaneous side effects of both clozapine and valproate [letter]. Intensive Care Med 2001; 27: 943

    Article  PubMed  CAS  Google Scholar 

  110. Kristensen SH, Porksen NK. Clozapine and diabetic ketoacidosis [in Danish]. Ugeskr Laeger 2003; 165: 475–6

    PubMed  Google Scholar 

  111. Short JA, Nolan JA. Neuroleptic malignant syndrome and hyperosmolar, non-ketotic hyperglycaemic coma. Pract Diabetes Int 1995; 12: 138–9

    Article  Google Scholar 

  112. Sobel M, Jaggers ED, Franz MA. New-onset diabetes mellitus associated with the initiation of quetiapine treatment [letter]. J Clin Psychiatry 1999; 60: 556–7

    Article  PubMed  CAS  Google Scholar 

  113. Domon SE, Cargile CS. Quetiapine-associated hyperglycemia and hypertriglyceridemia [letter]. J Am Acad Child Adolesc Psychiatry 2002; 41: 495–6

    Article  PubMed  Google Scholar 

  114. Wirshing DA, Pierre JM, Eyeler J, et al. Risperidone-associated new-onset diabetes. Biol Psychiatry 2001; 50: 148–9

    Article  PubMed  CAS  Google Scholar 

  115. Yang SH, McNeely MJ. Rhabdomyolysis, pancreatitis and hyperglycemia with ziprasidone [letter]. Am J Psychiatry 2002; 159: 1435

    Article  PubMed  Google Scholar 

  116. Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001; 16: 63–74

    Article  PubMed  CAS  Google Scholar 

  117. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001; 11: 25–32

    Article  PubMed  CAS  Google Scholar 

  118. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002; 14: 59–64

    PubMed  Google Scholar 

  119. Ananth J, Venkatesh R, Burgoyne K, et al. Atypical antipsychotic drug use and diabetes. Psychother Psychosom 2002; 71: 244–54

    Article  PubMed  Google Scholar 

  120. Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabetes. Am J Med 2001; 111: 716–23

    Article  PubMed  CAS  Google Scholar 

  121. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002; 22: 841–52

    Article  PubMed  CAS  Google Scholar 

  122. Koller EA, Cross JT, Doraiswamy PM, et al. Risperidone-associated diabetes melllitus: a pharmacovigilance study. Pharmacotherapy 2003; 23: 735–44

    Article  PubMed  CAS  Google Scholar 

  123. Ishigooka J, Murasaki M, Miura S. Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan. Psychiatry Clin Neurosci 2001; 55: 353–63

    Article  PubMed  CAS  Google Scholar 

  124. O’Neil MJ, Smith A, Heckelman PE, editors. The Merck Index: an encyclopedia of chemicals, drugs, and biologicals. 13th ed. Whitehouse Station (NJ): Merck & Co, 2001

    Google Scholar 

  125. Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm 1996; 53: 2079–81

    PubMed  CAS  Google Scholar 

  126. Spivak B, Roitman S, Vered Y, et al. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuro-pharmacol 1998; 21: 245–50

    CAS  Google Scholar 

  127. Dursun SM, Szemis A, Andrews H, et al. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. J Psychiatry Neurosci 1999; 24: 453–5

    PubMed  CAS  Google Scholar 

  128. Gaulin BD, Markowitz JS, Caley CF, et al. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999; 156: 1270–2

    PubMed  CAS  Google Scholar 

  129. Spivak B, Lamschtein C, Talmon Y, et al. The impact of clozapine treatment on serum lipids in chronic schizophrenic patients. Clin Neuropharmacol 1999; 22: 98–101

    Article  PubMed  CAS  Google Scholar 

  130. Wiltfang J, Schenk-Dapra B, Stiens G, et al. Clozapine-associated elevation of plasma cholinesterase. Eur Arch Psychiatry Clin Neurosci 2001; 251: 269–71

    Article  PubMed  CAS  Google Scholar 

  131. Pande S, Procyshyn RM, Nazerali M, et al. Do triglycerides modulate the effectiveness of clozapine? Int Clin Psychopharmacol 2002; 17: 197–9

    Article  PubMed  CAS  Google Scholar 

  132. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999; 60: 767–70

    Article  PubMed  CAS  Google Scholar 

  133. Sheitman BB, Bird PM, Binz W, et al. Olanzapine-induced elevation of plasma triglyceride levels [letter]. Am J Psychiatry 1999; 156: 1471–2

    PubMed  CAS  Google Scholar 

  134. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001; 21: 369–74

    Article  PubMed  CAS  Google Scholar 

  135. Nguyen M, Murphy T. Olanzapine and hypertriglyceridemia [letter]. J Am Acad Child Adolesc Psychiatry 2001; 40: 133

    Article  PubMed  CAS  Google Scholar 

  136. Martin A, L’Ecuyer S. Triglyceride, cholesterol and weight changes among risperidone-treated youths: a retrospective study. Eur Child Adolesc Psychiatry 2002; 11: 129–33

    Article  PubMed  CAS  Google Scholar 

  137. Cohen S, Fitzgerald B, Okos A, et al. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. J Clin Psychiatry 2003; 64: 60–2

    Article  PubMed  CAS  Google Scholar 

  138. Wetterling T. Hyperlipidemia: side-effect of the treatment with an atypical antipsychotic (zotepine) [in German]? Psychiatr Prax 2002; 29: 438–40

    Article  PubMed  Google Scholar 

  139. Ghaeli P, Dufresne RL. Elevated serum triglycerides with clozapine resolved with risperidone in four patients. Pharmacotherapy 1999; 19: 1099–101

    Article  PubMed  CAS  Google Scholar 

  140. Koro CE, Fedder DO, L’Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002; 59: 1021–6

    Article  PubMed  CAS  Google Scholar 

  141. Atmaca M, Kuloglu M, Tezcan E, et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003; 64: 598–604

    Article  PubMed  CAS  Google Scholar 

  142. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425–32

    Article  PubMed  CAS  Google Scholar 

  143. Woods SC, Kaiyala K, Porte D, et al. Food intake and energy balance. In: Porte D, Sherwin RS, editors. Diabetes mellitus. 5th ed. Stamford (CT): Appleton & Lange, 1997: 175–92

    Google Scholar 

  144. Shimabukuro M, Koyama K, Chen G, et al. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci U S A 1997; 94: 4637–41

    Article  PubMed  CAS  Google Scholar 

  145. Friedman JM. Leptin, leptin receptors, and the control of body weight. Nutr Rev 1998; 56: S38–46

    Article  PubMed  CAS  Google Scholar 

  146. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999; 341: 879–84

    Article  PubMed  CAS  Google Scholar 

  147. Segal KR, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996; 45: 988–91

    Article  PubMed  CAS  Google Scholar 

  148. Haffner SM, Miettinen H, Mykkänen L, et al. Leptin concentrations and insulin sensitivity in normoglycemic men. Int J Obes Relat Metab Disord 1997; 21: 393–9

    Article  PubMed  CAS  Google Scholar 

  149. Girard J. Is leptin the link between obesity and insulin resistance? Diabetes Metab 1997; 23: 16–24

    PubMed  CAS  Google Scholar 

  150. Kolaczynski JW, Nyce MR, Considine RV, et al. Acute and chronic effect of insulin on leptin production in humans: studies in vivo and in vitro. Diabetes 1996; 45: 699–701

    Article  PubMed  CAS  Google Scholar 

  151. Tanizawa Y, Okuya S, Ishihara H, et al. Direct stimulation of basal insulin secretion by physiological concentrations of leptin in pancreatic beta cells. Endocrinology 1997; 138: 4513–6

    Article  PubMed  CAS  Google Scholar 

  152. Seufert J, Kieffer TJ, Leech CA, et al. Leptin suppression of insulin secretion and gene expression in human pancreatic islets: implications for the development of adipogenic diabetes mellitus. J Clin Endocrinol Metab 1999; 84: 670–6

    Article  PubMed  CAS  Google Scholar 

  153. Brömel T, Blum WF, Ziegler A, et al. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 1998; 3: 76–80

    Article  PubMed  Google Scholar 

  154. Hinze-Selch D, Deuschle M, Weber B, et al. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology (Berl) 2000; 149: 163–9

    Article  CAS  Google Scholar 

  155. Hägg S, Söderberg S, Ahrén B, et al. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J Clin Psychiatry 2001; 62: 843–8

    Article  PubMed  Google Scholar 

  156. Monteleone P, Fabrazzo M, Tortorella A, et al. Pronounced, early increase in circulating leptin predicts lower weight gain during clozapine treatment. J Clin Psychopharmacol 2002; 22: 424–6

    Article  PubMed  CAS  Google Scholar 

  157. International classification of diseases. 10th rev. Geneva: World Health Organization, 1992

  158. Eder U, Mangweth B, Ebenbichler C, et al. Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry 2001; 158: 1719–22

    Article  PubMed  CAS  Google Scholar 

  159. Kraus T, Haack M, Schuld A, et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999; 156: 312–4

    PubMed  CAS  Google Scholar 

  160. Herran A, Garcia-Unzueta MT, Amado JA, et al. Effects of long-term treatment with antipsychotics on serum leptin levels. Br J Psychiatry 2001; 179: 59–62

    Article  PubMed  CAS  Google Scholar 

  161. Atmaca M, Kuloglu M, Tezcan E, et al. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol [letter]. Schizophr Res 2003; 60: 99–100

    Article  PubMed  Google Scholar 

  162. Klarlund JK, Cherniak AD, Conway BR, et al. Mechanisms of insulin action. In: Porte D, Sherwin RS, editors. Diabetes mellitus. 5th ed. Stamford (CT): Appleton & Lange, 1997: 75–93

    Google Scholar 

  163. Harris M, Cahill G. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039–57

    Google Scholar 

  164. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607

    Article  PubMed  CAS  Google Scholar 

  165. Melkersson K, Khan A, Hilding A, et al. Different effects of antipsychotic drugs on insulin release in vitro. Eur Neuropsychopharmacol 2001; 11: 327–32

    Article  PubMed  CAS  Google Scholar 

  166. Melkersson K. Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro. Eur Neuropsychopharmacol 2004; 14: 115–9

    Article  PubMed  CAS  Google Scholar 

  167. Hauner H, Röhrig K, Hedebrand J, et al. No evidence for a direct effect of clozapine on fat-cell formation and production of leptin and other fat-cell-derived factors. Mol Psychiatry 2003; 8: 258–9

    Article  PubMed  CAS  Google Scholar 

  168. Melkersson K, Hulting A-L, Brismar K. Reply: body weight gain, insulin, and leptin in olanzapine-treated patients [letter]. J Clin Psychiatry 2001; 62: 903–4

    Google Scholar 

  169. Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Comphr Psychiatry 1996; 37: 68–73

    Article  CAS  Google Scholar 

  170. Gopalaswamy AK, Morgan R. Too many chronic mentally disabled patients are too fat. Acta Psychiatr Scand 1985; 72: 254–8

    Article  PubMed  CAS  Google Scholar 

  171. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999; 60: 215–20

    Article  PubMed  CAS  Google Scholar 

  172. Kelly C, McCreadie RG. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry 1999; 156: 1751–7

    PubMed  CAS  Google Scholar 

  173. Braceland FJ, Meduna LJ, Vaichulis JA. Delayed action of insulin in schizophrenia. Am J Psychiatry 1945; 102: 108–10

    Google Scholar 

  174. Ryan MCM, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160: 284–9

    Article  PubMed  Google Scholar 

  175. Depres JP. Visceral obesity: a component of the insulin resistance-dyslipidemic syndrome. Can J Cardiol 1994; 10: 17B-22B

    Google Scholar 

  176. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001; 62 Suppl. 27: 15–26

    PubMed  CAS  Google Scholar 

  177. Lindenmayer J-P, Nathan A-M, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001; 62 Suppl. 23: 30–8

    PubMed  CAS  Google Scholar 

  178. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001; 46: 273–81

    PubMed  CAS  Google Scholar 

  179. Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 2001; 62 Suppl. 27: 27–34

    PubMed  CAS  Google Scholar 

  180. Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 2002; 16: 77–89

    Article  PubMed  CAS  Google Scholar 

  181. Luna B, Feinglos MN. Drug-induced hyperglycemia. JAMA 2001; 286: 1945–8

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors have no conflicts of interest that are relevant to the content of this manuscript. The work was supported by grants from the Swedish Society of Medicine.

Author information

Authors and Affiliations

  1. Sollentuna Psychiatric Polyclinic and Department of Molecular Medicine, Karolinska Institute, Stockholm, Sweden

    Kristina Melkersson

  2. Department of Medical Sciences, Clinical Pharmacology, University Hospital, Uppsala, Sweden

    Marja-Liisa Dahl

Authors
  1. Kristina Melkersson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marja-Liisa Dahl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kristina Melkersson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Melkersson, K., Dahl, ML. Adverse Metabolic Effects Associated with Atypical Antipsychotics. Drugs 64, 701–723 (2004). https://doi.org/10.2165/00003495-200464070-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200464070-00003

Keywords

Search

Navigation